Skip to main content
. 2012 Nov 5;31(6):744–751. doi: 10.1200/JCO.2012.43.8820

Fig A2.

Fig A2.

(A to D) Pathologic and (E to H) clinical response for (A, E) overall, (B, F) disease-free, (C, G) locoregional recurrence–free, and (D, H) distant metastasis–free survival. The landmark point was set at the time of response evaluation.